ImmunityBio (IBRX) Income from Continuing Operations (2014 - 2026)
ImmunityBio (IBRX) posted quarterly Income from Continuing Operations of 632788000.0 for Q1 2026, down 388.01% year-over-year from 219707512.55 in Q1 2025, and down 921.32% quarter-over-quarter from 61958000.0 in Q4 2025.
Powered by 
Analysis
ImmunityBio (IBRX) Income from Continuing Operations (2014 - 2026) Analysis & Trends
ImmunityBio (IBRX) has reported Income from Continuing Operations for 13 consecutive years, with 632788000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 388.01% year-over-year to 632788000.0; the TTM figure through Mar 2026 stood at 854629000.0 (down 108.86% YoY), while the FY2025 annual figure was 351472000.0, up 15.03% from the prior year.
- Income from Continuing Operations declined to 632788000.0 in Q1 2026 per IBRX's latest filing, from 61958000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 59179000.0 in Q4 2024 and bottomed at 632788000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 141124235.29 across 5 years, with a median of 108326000.0 in 2022.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations soared 74.65% — and 2026, when it tumbled 388.01%.
- ImmunityBio's Income from Continuing Operations stood at 108326000.0 in 2022, then tumbled by 115.47% to 233414000.0 in 2023, then jumped by 74.65% to 59179000.0 in 2024, then retreated by 4.7% to 61958000.0 in 2025, then slumped by 921.32% to 632788000.0 in 2026.
- Business Quant data shows IBRX's Income from Continuing Operations at 632788000.0 in Q1 2026, 61958000.0 in Q4 2025, and 67309000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -13.27 Mn |
| 10 | ImmunityBio | 8.47 Bn | 8.12 Bn | 50.94 Mn | -230.39 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -230.39 Mn |
| Mar 31, 2026 | -632.80 Mn |
| Dec 31, 2025 | -61.96 Mn |
| Sep 30, 2025 | -67.27 Mn |
| Jun 30, 2025 | -92.61 Mn |
| Mar 31, 2025 | -129.67 Mn |
| Dec 31, 2024 | -59.18 Mn |
| Sep 30, 2024 | -85.75 Mn |
| Jun 30, 2024 | -134.58 Mn |
| Mar 31, 2024 | -134.13 Mn |
| Dec 31, 2023 | -233.41 Mn |
| Sep 30, 2023 | -95.64 Mn |
| Jun 30, 2023 | -138.21 Mn |
| Mar 31, 2023 | -116.58 Mn |
| Dec 31, 2022 | -108.33 Mn |
| Sep 30, 2022 | -111.16 Mn |
| Jun 30, 2022 | -94.84 Mn |
| Mar 31, 2022 | -103.00 Mn |
| Dec 31, 2021 | -91.55 Mn |
| Sep 30, 2021 | -88.43 Mn |